-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At the time of the 2021 annual report disclosure season, the number of listed companies in the pharmaceutical industry that issued performance forecasts and performance bulletins increased
.
Among them, on the evening of January 20, Wohua Medicine disclosed the 2021 annual report earlier in the pharmaceutical and biological industry, and more other companies only issued performance forecasts
.
The data shows that Wohua Pharmaceutical's performance in 2021 is "stable and slightly down", and its operating income has fallen by 6.
3% year-on-year to 943 million yuan; the net profit attributable to shareholders of listed companies has fallen by 8.
6% year-on-year to 163 million yuan
.
It is reported that the current performance situation of Wohua Medicine is mainly due to factors such as the sharp rise in the prices of raw materials of Chinese herbal medicines, packaging materials, energy and other factors during the reporting period
.
The company said: "In 2021, the company and the industry will feel the impact of the continuous rise in raw material and energy prices in all aspects
.
" In this regard, Wohua Pharmaceutical's solution is to optimize production processes and improve procurement accuracy to reduce costs.
cost
.
For example, in early 2021, Wohua Medicine started the production process optimization project of Gushukang capsules, which effectively reduced the water, alcohol, steam and sewage treatment costs and product costs, and the extraction space increased by 16.
7%
.
Through Wohua Medicine, it can be foreseen that in 2021, many pharmaceutical companies are constantly coming up with new solutions to deal with various problems in the development of the industry, in order to promote the growth of performance
.
According to incomplete statistics, as of January 20, 74 listed companies in the pharmaceutical and biological industry have released 2021 performance forecasts or performance reports
.
Based on the median forecasted net profit, 80% of pharmaceutical companies will increase their net profit in 2021
.
Six of them, including Jimin Medical, Rejing Bio, Xinlitai, Kangenbei, Jiu'an Medical, and Teyi Pharmaceutical, are expected to increase their net profit by more than 200%
.
In addition, 12 companies including Mingde Bio, Oriental Bio, and Zhongsheng Pharmaceutical are expected to increase their net profit by more than 100%.
.
Taking Teyi Pharmaceutical as an example, according to its performance forecast, the company will focus on the development of Chinese patent medicines under the background of the current national industrial policy strongly supporting the development of the Chinese medicine industry, and will increase the potential of Chinese patent medicines while expanding the core products.
Product market cultivation and development efforts; under the background of the implementation of the generic drug consistency evaluation policy, the company will take this opportunity to actively participate in the later centralized procurement and hospital bidding work, and increase the company's product marketing channels; in the company's "Xinning" Under the background that the "Pharmaceutical GMP Reconstruction and Expansion Project" is about to be completed and put into production, the company will increase the market promotion of APIs and increase the market share of existing APIs
.
In addition, under the premise that healthy consumption has become a major demand for social development, the company will continue to deepen the layout of the industrial chain based on its own development, scientifically plan the future development direction, improve the company's comprehensive competitiveness and overall ability to resist market fluctuations, and achieve sustainable development.
stable development
.
Regarding the reasons for the changes in the performance forecast of the pharmaceutical industry in 2021, some analysts pointed out that some of these companies with pre-increased performance are endogenous growth, some are growing because of the low performance base in 2020, and some are due to the high growth of the industry segment.
resulting in performance growth
.
It is worth noting that high-growth companies in 2021 are mainly concentrated in CXO, API, in vitro diagnostics (IVD), diagnostic consumables, pharmaceutical equipment and other sectors.
Some personalized and competitive companies have also achieved good performance, while pharmaceuticals There are not many endogenous high-growth groups in enterprises
.
For example, in the pharmaceutical equipment sector, Chutian Technology expects that its profit in 2021 will increase by 149.
33%-199.
20% year-on-year, to 500 million to 600 million yuan
.
During the reporting period, the company focused on the development of biopharmaceutical equipment, and has basically completed the layout of biopharmaceutical front-end equipment
.
As for the good performance of the pharmaceutical equipment sector, analysts pointed out that this is mainly due to the rapid development of the biomedical industry and the strong demand for diagnostic consumables and pharmaceutical equipment.
.
Among them, on the evening of January 20, Wohua Medicine disclosed the 2021 annual report earlier in the pharmaceutical and biological industry, and more other companies only issued performance forecasts
.
The data shows that Wohua Pharmaceutical's performance in 2021 is "stable and slightly down", and its operating income has fallen by 6.
3% year-on-year to 943 million yuan; the net profit attributable to shareholders of listed companies has fallen by 8.
6% year-on-year to 163 million yuan
.
It is reported that the current performance situation of Wohua Medicine is mainly due to factors such as the sharp rise in the prices of raw materials of Chinese herbal medicines, packaging materials, energy and other factors during the reporting period
.
The company said: "In 2021, the company and the industry will feel the impact of the continuous rise in raw material and energy prices in all aspects
.
" In this regard, Wohua Pharmaceutical's solution is to optimize production processes and improve procurement accuracy to reduce costs.
cost
.
For example, in early 2021, Wohua Medicine started the production process optimization project of Gushukang capsules, which effectively reduced the water, alcohol, steam and sewage treatment costs and product costs, and the extraction space increased by 16.
7%
.
Through Wohua Medicine, it can be foreseen that in 2021, many pharmaceutical companies are constantly coming up with new solutions to deal with various problems in the development of the industry, in order to promote the growth of performance
.
According to incomplete statistics, as of January 20, 74 listed companies in the pharmaceutical and biological industry have released 2021 performance forecasts or performance reports
.
Based on the median forecasted net profit, 80% of pharmaceutical companies will increase their net profit in 2021
.
Six of them, including Jimin Medical, Rejing Bio, Xinlitai, Kangenbei, Jiu'an Medical, and Teyi Pharmaceutical, are expected to increase their net profit by more than 200%
.
In addition, 12 companies including Mingde Bio, Oriental Bio, and Zhongsheng Pharmaceutical are expected to increase their net profit by more than 100%.
.
Taking Teyi Pharmaceutical as an example, according to its performance forecast, the company will focus on the development of Chinese patent medicines under the background of the current national industrial policy strongly supporting the development of the Chinese medicine industry, and will increase the potential of Chinese patent medicines while expanding the core products.
Product market cultivation and development efforts; under the background of the implementation of the generic drug consistency evaluation policy, the company will take this opportunity to actively participate in the later centralized procurement and hospital bidding work, and increase the company's product marketing channels; in the company's "Xinning" Under the background that the "Pharmaceutical GMP Reconstruction and Expansion Project" is about to be completed and put into production, the company will increase the market promotion of APIs and increase the market share of existing APIs
.
In addition, under the premise that healthy consumption has become a major demand for social development, the company will continue to deepen the layout of the industrial chain based on its own development, scientifically plan the future development direction, improve the company's comprehensive competitiveness and overall ability to resist market fluctuations, and achieve sustainable development.
stable development
.
Regarding the reasons for the changes in the performance forecast of the pharmaceutical industry in 2021, some analysts pointed out that some of these companies with pre-increased performance are endogenous growth, some are growing because of the low performance base in 2020, and some are due to the high growth of the industry segment.
resulting in performance growth
.
It is worth noting that high-growth companies in 2021 are mainly concentrated in CXO, API, in vitro diagnostics (IVD), diagnostic consumables, pharmaceutical equipment and other sectors.
Some personalized and competitive companies have also achieved good performance, while pharmaceuticals There are not many endogenous high-growth groups in enterprises
.
For example, in the pharmaceutical equipment sector, Chutian Technology expects that its profit in 2021 will increase by 149.
33%-199.
20% year-on-year, to 500 million to 600 million yuan
.
During the reporting period, the company focused on the development of biopharmaceutical equipment, and has basically completed the layout of biopharmaceutical front-end equipment
.
As for the good performance of the pharmaceutical equipment sector, analysts pointed out that this is mainly due to the rapid development of the biomedical industry and the strong demand for diagnostic consumables and pharmaceutical equipment.
